Tuesday, July 09, 2019 11:39:17 AM
Compiled: AUSTRALIA'S TGA: 07/08/19
______________________________________________________________________________________________
The Australian attitude toward healthcare is 180 degrees away from the U.S. for profit system.
“These findings show Australians want future access to breakthrough medicines. What is critical is to balance this innovation and affordability with the expectations of Australians. This will challenge some of our long-standing healthcare policies. We only have to look at the evolution in precision medicine and the impact targeted therapies can have on health outcomes and costs.” (from kevli33)
https://medicinesaustralia.com.au/from-the-chief-executive/new-findings-confirm-australians-place-high-value-on-the-pbs-but-acknowledge-its-shortfalls/
Discussion of possible commercial sales under Aussie SAS program:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149077207
More info on SAS:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147172732
Australia sees the need for population based screening for dementia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148875697
Aussie press coverage 5/6/19 on Parkinson's dementia trials:
https://pressfrom.info/au/lifestyle/health/-121247-experimental-pill-shows-promising-results-for-parkinson-s.html
Top 20 pharmas with an Australian company that would make a good Anavex partner:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148731195I
See note on the above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148733750
Australia may get us Canada:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148710704&txt2find=tga
Aussie P2/3 - link to study:
https://www.australianclinicaltrials.gov.au/anzctr/trial/NCT03790709
AIBL study (Australian Imaging Biomarker Lifestyle Study)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148157259&txt2find=AIBL
Study was cited by Missling:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154210
April 5 2019 presentation to Australian healthcare workers concerning new trial approval protocol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148220574
The timeline and requirements for provisional approval in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148221459
AUSTRAILIA TGA is different from the U.S. FDA
https://www.slideshare.net/TherapeuticGoodsAdministration/clinical-trials-tga-role
Arguments for accelerated approval for 2-73.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143620275
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143624077
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144651100
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144731123
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144982778
On the possibility of miss diagnosis in Australia.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148065519
2014 paper on diagnostic accuracy in Alzheimer's in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148065519
The facts about clinical trials performed in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148074963
Provisional approval in Australia may not require completion of the P3.. (links thanks to JonJones325)
https://www.tga.gov.au/publication/provisional-determination-eligibility-criteria
https://www.tga.gov.au/publication/provisional-determination
https://www.tga.gov.au/presentation-provisional-approval-pathway-prescription-medicines
December 2018 discussion of Possible Provisional approval in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145445997
Definition of Major Therapeutic Advance in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144734105
Feedback from Down Under - KaRa MINDS Institute participating as of 10/19/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146469112
Speeding up trials in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144956115
______________________________________________________________________________________________
The Australian attitude toward healthcare is 180 degrees away from the U.S. for profit system.
“These findings show Australians want future access to breakthrough medicines. What is critical is to balance this innovation and affordability with the expectations of Australians. This will challenge some of our long-standing healthcare policies. We only have to look at the evolution in precision medicine and the impact targeted therapies can have on health outcomes and costs.” (from kevli33)
https://medicinesaustralia.com.au/from-the-chief-executive/new-findings-confirm-australians-place-high-value-on-the-pbs-but-acknowledge-its-shortfalls/
Discussion of possible commercial sales under Aussie SAS program:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149077207
More info on SAS:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147172732
Australia sees the need for population based screening for dementia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148875697
Aussie press coverage 5/6/19 on Parkinson's dementia trials:
https://pressfrom.info/au/lifestyle/health/-121247-experimental-pill-shows-promising-results-for-parkinson-s.html
Top 20 pharmas with an Australian company that would make a good Anavex partner:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148731195I
See note on the above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148733750
Australia may get us Canada:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148710704&txt2find=tga
Aussie P2/3 - link to study:
https://www.australianclinicaltrials.gov.au/anzctr/trial/NCT03790709
AIBL study (Australian Imaging Biomarker Lifestyle Study)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148157259&txt2find=AIBL
Study was cited by Missling:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154210
April 5 2019 presentation to Australian healthcare workers concerning new trial approval protocol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148220574
The timeline and requirements for provisional approval in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148221459
AUSTRAILIA TGA is different from the U.S. FDA
https://www.slideshare.net/TherapeuticGoodsAdministration/clinical-trials-tga-role
Arguments for accelerated approval for 2-73.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143620275
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143624077
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144651100
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144731123
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144982778
On the possibility of miss diagnosis in Australia.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148065519
2014 paper on diagnostic accuracy in Alzheimer's in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148065519
The facts about clinical trials performed in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148074963
Provisional approval in Australia may not require completion of the P3.. (links thanks to JonJones325)
https://www.tga.gov.au/publication/provisional-determination-eligibility-criteria
https://www.tga.gov.au/publication/provisional-determination
https://www.tga.gov.au/presentation-provisional-approval-pathway-prescription-medicines
December 2018 discussion of Possible Provisional approval in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145445997
Definition of Major Therapeutic Advance in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144734105
Feedback from Down Under - KaRa MINDS Institute participating as of 10/19/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146469112
Speeding up trials in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144956115
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM

